سعر ستارليدين 60مجم 10 اقراص 2022

Nateglinide 60 mg film-coated oral tablets, 10 per pack, marketed in Egypt by International Drug Agency (IDI); a short-acting insulin secretagogue for type 2 diabetes.

• Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.Population: AdultsDailyMed (U.S. National Library of Medicine)

• Upper respiratory infection, back pain, flu symptoms, dizziness, arthropathy, diarrhea, accidental trauma, bronchitis, coughing; hypoglycemia; weight gain; increased uric acid; postmarketing rash, itching, urticaria, jaundice, cholestatic hepatitis and elevated liver enzymes.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• History of hypersensitivity to nateglinide or its inactive ingredients.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• All glinides can cause hypoglycemia, which may be severe; risk increases with skipped meals, exercise changes, other antidiabetics and renal or hepatic impairment; educate patients and monitor blood glucose.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• No conclusive evidence of macrovascular risk reduction; not for type 1 diabetes or diabetic ketoacidosis.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• NSAIDs, salicylates, MAO inhibitors, non-selective beta-blockers, anabolic hormones, guanethidine, CYP2C9 inhibitors (amiodarone, fluconazole, voriconazole, sulfinpyrazone), alcohol, gymnema, glucomannan, thioctic acidMay increase glucose-lowering effect and hypoglycemia risk; dose reduction and more frequent glucose monitoring may be required.DailyMed (U.S. National Library of Medicine)
• Thiazides, corticosteroids, thyroid products, sympathomimetics, somatropin, somatostatin analogues, CYP inducers (rifampin, phenytoin, St John's Wort)May reduce glucose-lowering effect; dose increase and more frequent monitoring may be required.DailyMed (U.S. National Library of Medicine)
• Beta-blockers, clonidine, guanethidine, reserpineMay blunt signs and symptoms of hypoglycemia; increase glucose monitoring.DailyMed (U.S. National Library of Medicine)

• Available data are insufficient to identify a drug-associated risk of major birth defects or miscarriage; poorly controlled diabetes carries maternal and fetal risks; use only if potential benefit justifies potential risk.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• No human data; present in rat milk; because of potential hypoglycemia in breastfed infants, use while breastfeeding is not recommended.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Nateglinide: Amino-acid derivative that stimulates rapid, short-lived insulin secretion from pancreatic beta cells by closing ATP-dependent potassium channels; action depends on functioning beta cells.